SequelSEC

Regenerative Medical Technology Group Inc. RMTG

Retail-Retail Stores, NEC · CIK 0001760026 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$4.02M
Fiscal year ended 2026-06-30
Operating income
$565.98K
Fiscal year ended 2026-06-30
Free cash flow
$288.48K
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$612.54KMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.05Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue0.1×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Retail-Retail Stores, NEC filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue11.8%100th
FCF margin-25.7%0th
Current ratio0.03x8th
Net margin-153.2%9th
Revenue YoY growth24.2%91th
Gross margin55.1%82th
Operating margin-17.0%18th

Regenerative Medical Technology Group Inc. (RMTG) reported revenue of $4.02M and net income of -$2.91M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Regenerative Medical Technology Group Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Retail-Retail Stores, NEC.

Income

Regenerative Medical Technology Group Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$4.02M$2.64M$1.57M$1.18M$983.32K$1.36M$1.51M$986.31K$793.33K$817.03K
Cost of revenue$1.44M$872.86K$792.43K$678.98K$397.69K$420.45K$530.64K$239.25K$266.44K$248.04K
Gross profit$2.58M$1.77M$779.50K$501.56K$585.63K$943.89K$980.18K$747.06K$526.88K$568.99K
Operating income$565.98K$229.78K-$306.27K-$445.76K-$250.09K$134.96K$380.62K$19.65K-$213.98K-$105.10K
Net income-$2.91M-$876.27K-$1.39M-$4.35M-$1.44M-$760.04K-$638.19K-$887.15K-$2.08M-$1.96M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 13.22Mshares 13.14MUnavailableshares 12.54Mshares 12.54Mshares 12.54MUnavailableshares 12.54Mshares 12.49Mshares 12.49M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.22$-0.07Unavailable$-0.35$-0.12$-0.06Unavailable$-0.07$-0.17$-0.16
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$619.16K$475.81K$389.32K$277.70K$207.45K$245.57K$113.11K$264.08K$262.04K$159.09K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Regenerative Medical Technology Group Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$1.32M$1.06M$956.72K$1.19M$1.61M$1.22M$1.17MUnavailableUnavailable$579.35K
Total assets$5.85M$5.01M$4.49M$4.52M$4.49M$3.98M$3.82MUnavailable$3.05M$3.08M
Current assets$2.28M$1.57M$1.22M$1.51M$1.91M$1.45M$1.25MUnavailable$686.57K$668.36K
Total liabilities$45.11M$40.63M$40.54M$34.57M$33.51M$32.10M$31.18MUnavailable$28.88M$26.84M
Current liabilities$42.61M$38.20M$38.13M$17.27M$30.54M$29.88M$28.97MUnavailable$26.42M$24.36M
Total equity incl. NCI-$39.26M-$36.36M-$36.05M-$30.05M-$29.02M-$28.12M-$27.36M-$26.72M-$25.83M-$23.76M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$481.17K$298.20K$159.28K$155.89K$105.69K$22.83K$10.12KUnavailable$6.68KUnavailable
Accounts receivable$110.24K$34.82K$43.82K$114.01K$36.68K$16.31K$22.60KUnavailable$24.19K$43.51K
Goodwill$1.68M$1.68M$1.68M$1.68M$1.68M$1.68M$1.68MUnavailable$1.68M$1.68M
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$1.27MUnavailableUnavailable$554.52K

Cash flow

Regenerative Medical Technology Group Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow$331.97K$102.12K$38.20K-$203.73K-$598.09K$57.11K$379.39K$272.94K$90.40K$107.97K
Capital expenditures$43.50K$315.39K$267.17K$224.83KUnavailableUnavailable$50.00K$53.61K$52.66K$59.15K
Investing cash flow-$43.50K-$315.39K-$267.17K-$224.83KUnavailableUnavailable-$50.00K-$53.61K-$52.66K-$59.15K
Financing cash flow-$26.62K$318.00K$0$0UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$90.81K$97.69K$98.34K$76.08K$54.83K$51.81K-$27.81K$88.83K$82.97K$76.57K

Derived

Regenerative Medical Technology Group Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow$288.48K-$213.27K-$228.98K-$428.56KUnavailableUnavailable$329.39K$219.33K$37.74K$48.81K
Gross margin64.1%66.9%49.6%42.5%59.6%69.2%64.9%75.7%66.4%69.6%
Operating margin14.1%8.7%-19.5%-37.8%-25.4%9.9%25.2%2.0%-27.0%-12.9%
FCF margin7.2%-8.1%-14.6%-36.3%UnavailableUnavailable21.8%22.2%4.8%6.0%
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio0.05x0.04x0.03x0.09x0.06x0.05x0.04xUnavailable0.03x0.03x
Revenue YoY growth309.1%93.5%4.0%19.7%23.9%67.0%145.4%52.5%119.5%3.9%
Net margin-72.2%-33.2%-88.6%-368.8%-146.8%-55.7%-42.2%-89.9%-261.8%-240.0%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenue1.1%11.9%17.0%19.0%UnavailableUnavailable3.3%5.4%6.6%7.2%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RMTG in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-19View SEC filing
10-Q · Filed 2026-06-09View SEC filing
10-K · Filed 2026-05-14View SEC filing
10-Q · Filed 2025-11-19View SEC filing
10-Q · Filed 2025-08-19View SEC filing
10-Q · Filed 2025-05-20View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.